Intravitreal combination of dexamethasone sodium phosphate and bevacizumab in the treatment of exudative AMD

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Vakalis, N ^a   Echiadis, G ^a   Pervena, A ^a   Deligiannis, I ^a   Kavalarakis, E ^a   Giannikakis, S ^a   Papaefthymiou, I ^a  

^a ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DEXAMETHASONE; DEXAMETHASONE 21-PHOSPHATE; DRUG COMBINATION;

AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; FEMALE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MALE; MIDDLE AGED; PATHOLOGY; PILOT STUDY; RETINA; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DEXAMETHASONE; DRUG COMBINATIONS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PILOT PROJECTS; RETINA; TREATMENT OUTCOME;

EID: 84923769766     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08627     Document Type: Article

References (43)

1. Owen, C G., Fletcher, A. E., Donoghue, M. & Rudnicka, A. R. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?. Br J Ophthalmol. 87, 312-17 (2003
2. Reidy, A. et al. Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. BMJ 316, 1643-6 (1998
3. Congdon, N. et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 122, 477-85 (2004
4. Friedman, D. S. et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 122, 564-72 (2004
5. Ng, E. W. & Adamis, A. P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 40, 352-68 (2005
6. Rosenfeld, P. J., Mosfeghi, A. A. & Puliafito, C. A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36, 331-5 (2005
7. Nachod, G. R. ACTH and cortisone in ocular disease. J AmMed Womens Assoc. 6, 453-5 (1951
8. Edelman, J. L., Lutz, D. & Castro, M. R. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-Aqueous barrier breakdown. Experimental Eye Research 80, 249-58 (2005
9. Singer, M. A. et al. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina 32, 1289-94 (2012
10. Bakri, S. J., Couch, S. M., McCannel, C. A. & Edwards, A. O. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 29, 573-578 (2009
11. Augustin, A. J., Puls, S. & Offermann, I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 27, 133-140 (2007
12. Ehmann, D. & Garcia, R. Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). Can J Ophthalmol.45, 36-40 (2010
13. Plate, K. H., Breier, G., Weich, H. A. & Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848 (1992
14. Adamis, A. P. et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun. 193, 631-638 (1993
15. Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992
16. Pierce, E. A., Avery, R. L., Foley, E. D., Aiello, L. P. & Smith, L. E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 92, 905-909 (1995
17. Nomura, M. et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem. 270, 28316-28324 (1995
18. Bao, Y., Lv, F. & Ma, Y. Effect of dexamethasone on expression of hypoxia inducible factor-1a and vascular endothelial growth factor in hypoxic mice. Zhongguo Fei Ai Za Zhi. 20;9, 143-6 (2006
19. Beatty, S., Koh, H., Phil, M., Henson, D. & Boulton, M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 45, 115-34 (2000
20. Anderson, D. H., Mullins, R. F., Hageman, G. S. & Johnson, L. V. A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 134, 411-31 (2002
21. Anderson, D.H. et al. The pivotal role of the complement system in aging and agerelated macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res. 29, 95-112 (2010
22. Harper, F. H., Liversidge, J., Thomson, A. W. & Forrester, J. V. Interphotoreceptor retinoid binding protein induced experimental autoimmune uveitis: an immunophenotypic analysis using alkaline phosphatase anti-Alkaline phosphatase staining, dual immunofluorescence and confocal microscopy. Curr Eye Res. 11, 129-134 (1992
23. Jerdan, J. A. et al. Proliferative vitreoretinopathy membranes: an immunohistochemical study. Ophthalmology 96, 801-810 (1989
24. Lopez, P. F. et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. AmJ Ophthalmol. 112, 647-656 (1991
25. Seregard, S., Algvere, P. V.&Berglin, L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol. 232, 325-329 (1994
26. Berse, B., Brown, L. F., Van deWater, L., Dvorak, H. F. & Senger, D. R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 3, 211-220 (1992
27. Polverini, P. J., Cotran, P. S., Gimbrone, M. Jr. & Unanue, E. R. Activated macrophages induce vascular proliferation. Nature 269, 804-806 (1977
28. Wahl, S. M. et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA. 84, 5788-5792 (1987
29. Hideyasu, O. H. et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 40, 1891-1898 (1999)
30. Ito, W. D. et al. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res. 80, 829-837 (1997
31. Arras, M. et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest. 101, 40-50 (1998
32. Stergiou, P. et al. Intravitreal combination of kenacort and avastin (ken-Av) for choroidal neovascular age-related macular degeneration. Cannes Retinal Festival N.144 (Sep 10 2006
33. Ranchod, T. M. et al. LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration. Retina 33, 1600-4 (2013
34. Steven, K. H. Adrenal cortical steroids. In: Drug facts and comparisons. 5th ed. St. Louis: Facts and Comparisons, Inc.; 122-128 (1997
35. Mains, J., Wilson, C. G. & Urquhart, A. ToF-SIMS analysis of dexamethasone distribution in the isolated perfused eye. Invest. Ophthalmol. Vis. Sci. 52, 8413-8419 (2011
36. Marieke, V. et al.Association of ranibizumab (Lucentis) or bevacizumab (Avastin) with dexamethasone and triamcinolone acetonide: An in vitro stability assessment. European Journal of Pharmaceutics and Biopharmaceutics. 78, 271-277 (2011
37. Chalam, K. V., Malkani, S. & Shah, V. A. Intravitreal dexamethasone effectively reduces postoperative inflammation after vitreoretinal surgery. Ophthalmic Surg Lasers Imaging. 34, 188-192 (2003
38. Apte, R. S. Regulation of angiogenesis by macrophages. Adv Exp Med Biol. 664, 15-19 (2010
39. Vakalis, N. et al. Intravitreal injection of dexamethasone in the treatment of diabetic macular edema. 7th Pan-Hellenic Vitreo-Retinal Meeting: Pathology of Retina, (13-15 January, 2012), Athens-Greece
40. Vakalis, N. et al. Intravitreal injection of dexamethasone in the treatment of retinal vein occlusion. 8th Pan-Hellenic Vitreo-Retinal Meeting: Pathology of Retina, (18-19 January, 2013), Athens-Greece
41. Vakalis, N. et al. Intravitreal injection of dexamethasone and bevacizumab in the treatment of exudative AMD. 8th Pan-Hellenic Vitreo-Retinal Meeting: Pathology of Retina, (18-19 January, 2013), Athens-Greece
42. Penfold, P. L., Wong, J. G., Gyory, J. & Billson, F. A. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol. 29, 188-192 (2001
43. Jermak, C. M., Dellacroce, J. T., Heffez, J. & Peyman, G. A. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 52, 503-522 (2007